267 related articles for article (PubMed ID: 16987804)
1. The JAK2 V617F mutation is absent in patients with erythrocytosis due to high oxygen affinity hemoglobin variants.
McClure RF; Hoyer JD; Mai M
Hemoglobin; 2006; 30(4):487-9. PubMed ID: 16987804
[TBL] [Abstract][Full Text] [Related]
2. Polycythemia vera: scientific advances and current practice.
Tefferi A; Spivak JL
Semin Hematol; 2005 Oct; 42(4):206-20. PubMed ID: 16210034
[TBL] [Abstract][Full Text] [Related]
3. A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Kralovics R; Passamonti F; Buser AS; Teo SS; Tiedt R; Passweg JR; Tichelli A; Cazzola M; Skoda RC
N Engl J Med; 2005 Apr; 352(17):1779-90. PubMed ID: 15858187
[TBL] [Abstract][Full Text] [Related]
4. Detection of JAK2 V617F as a first intention diagnostic test for erythrocytosis.
James C; Delhommeau F; Marzac C; Teyssandier I; Couédic JP; Giraudier S; Roy L; Saulnier P; Lacroix L; Maury S; Tulliez M; Vainchenker W; Ugo V; Casadevall N
Leukemia; 2006 Feb; 20(2):350-3. PubMed ID: 16341032
[No Abstract] [Full Text] [Related]
5. The 2001 World Health Organization and updated European clinical and pathological criteria for the diagnosis, classification, and staging of the Philadelphia chromosome-negative chronic myeloproliferative disorders.
Michiels JJ; De Raeve H; Berneman Z; Van Bockstaele D; Hebeda K; Lam K; Schroyens W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):307-40. PubMed ID: 16810609
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum erythropoietin levels in patients with Budd-Chiari syndrome secondary to polycythemia vera: clinical implications for the role of JAK2 mutation analysis.
Thurmes PJ; Steensma DP
Eur J Haematol; 2006 Jul; 77(1):57-60. PubMed ID: 16827884
[TBL] [Abstract][Full Text] [Related]
7. Detection of the activating JAK2 V617F mutation in paraffin-embedded trephine bone marrow biopsies of patients with chronic myeloproliferative diseases.
Horn T; Kremer M; Dechow T; Pfeifer WM; Geist B; Perker M; Duyster J; Quintanilla-Martinez L; Fend F
J Mol Diagn; 2006 Jul; 8(3):299-304. PubMed ID: 16825501
[TBL] [Abstract][Full Text] [Related]
8. The incidence of the JAK2 V617F mutation in patients with idiopathic erythrocytosis.
Percy MJ; Jones FG; Green AR; Reilly JT; McMullin MF
Haematologica; 2006 Mar; 91(3):413-4. PubMed ID: 16503548
[TBL] [Abstract][Full Text] [Related]
9. The role of JAK2 V617F mutation, spontaneous erythropoiesis and megakaryocytopoiesis, hypersensitive platelets, activated leukocytes, and endothelial cells in the etiology of thrombotic manifestations in polycythemia vera and essential thrombocythemia.
Bellucci S; Michiels JJ
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):381-98. PubMed ID: 16810614
[TBL] [Abstract][Full Text] [Related]
10. The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera.
Tefferi A; Lasho TL; Schwager SM; Strand JS; Elliott M; Mesa R; Li CY; Wadleigh M; Lee SJ; Gilliland DG
Cancer; 2006 Feb; 106(3):631-5. PubMed ID: 16369984
[TBL] [Abstract][Full Text] [Related]
11. Concomitant neutrophil JAK2 mutation screening and PRV-1 expression analysis in myeloproliferative disorders and secondary polycythaemia.
Tefferi A; Sirhan S; Lasho TL; Schwager SM; Li CY; Dingli D; Wolanskyj AP; Steensma DP; Mesa R; Gilliland DG
Br J Haematol; 2005 Oct; 131(2):166-71. PubMed ID: 16197445
[TBL] [Abstract][Full Text] [Related]
12. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates.
Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D
Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651
[TBL] [Abstract][Full Text] [Related]
13. New insights into the pathogenesis of JAK2 V617F-positive myeloproliferative disorders and consequences for the management of patients.
Villeval JL; James C; Pisani DF; Casadevall N; Vainchenker W
Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):341-51. PubMed ID: 16810610
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a new hemoglobin variant: Hb Badalona (beta31[B13]Leu-->Val).
Junca J; Villegas A; Ropero P; González FA; Motos A; Valverde F
Ann Hematol; 2002 Apr; 81(4):179-81. PubMed ID: 11976817
[TBL] [Abstract][Full Text] [Related]
15. Case 15-2006: the Budd-Chiari syndrome and V617F mutation in JAK2.
Spivak JL; Moliterno AR; Silver RT
N Engl J Med; 2006 Aug; 355(7):737; author reply 738. PubMed ID: 16914715
[No Abstract] [Full Text] [Related]
16. Two different mutations in codon 97 of the beta-globin gene cause Hb Malmö in Sweden.
Landin B; Berglund S; Wallman K
Am J Hematol; 1996 Jan; 51(1):32-6. PubMed ID: 8571935
[TBL] [Abstract][Full Text] [Related]
17. The V617F JAK2 mutation and the myeloproliferative disorders.
Percy MJ; McMullin MF
Hematol Oncol; 2005; 23(3-4):91-3. PubMed ID: 16285006
[TBL] [Abstract][Full Text] [Related]
18. [Acquired mutation of JAK2 tyrosine kinase and polycythaemia vera].
Pargade V; Darnige L; Gaussem P
Ann Biol Clin (Paris); 2006; 64(1):3-9. PubMed ID: 16420986
[TBL] [Abstract][Full Text] [Related]
19. A quantitative assay for JAK2(V617F) mutation in myeloproliferative disorders by ARMS-PCR and capillary electrophoresis.
Vannucchi AM; Pancrazzi A; Bogani C; Antonioli E; Guglielmelli P
Leukemia; 2006 Jun; 20(6):1055-60. PubMed ID: 16572198
[TBL] [Abstract][Full Text] [Related]
20. [New molecular markers within the chronic myeloproliferative disorders. II: the JAK2 mutation].
Larsen TS; Pallisgaard N; Christensen JH; Gram-Hansen P; Kerndrup GB; Møller MB; Hasselbalch HC
Ugeskr Laeger; 2006 Sep; 168(39):3299-303. PubMed ID: 17032592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
